Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00286806
Status:
COMPLETED
Last Update Posted:
2010-08-24
First Post:
2006-02-03
Brief Title:
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Sponsor:
Ascenta Therapeutics
Organization:
Ascenta Therapeutics
Study Overview
Official Title:
An Open-Label Multicenter Phase III Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer HRPC and Rising Prostate Specific Antigen PSA Levels Who Have Not Received Prior Chemotherapy
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter Phase III study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None